Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers

NCT01009788 is registered in ClinicalTrials.gov with Steven J Isakoff, MD, PhD as lead sponsor.

NCT NCT01009788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01009788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers
Lead sponsor
Steven J Isakoff, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
September 30, 2015
Enrollment
63 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 gene mutation, brca2 gene mutation, breast cancer, metastatic breast cancer